Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response
Worapol Ngamcherdtrakul, Moataz Reda, Molly A. Nelson, et al.
Advanced Materials (2021) Vol. 33, Iss. 31
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
Moataz Reda, Worapol Ngamcherdtrakul, Molly A. Nelson, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 126
STAT3 pathway in cancers: Past, present, and future
Hanqi Wang, Qi‐Wen Man, Fang‐Yi Huo, et al.
MedComm (2022) Vol. 3, Iss. 2
Open Access | Times Cited: 107
Bioorthogonal-Activated In Situ Vaccine Mediated by a COF-Based Catalytic Platform for Potent Cancer Immunotherapy
Mengyu Sun, Zhengwei Liu, Li Wu, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 9, pp. 5330-5341
Closed Access | Times Cited: 84
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
Yamei Hu, Zigang Dong, Kangdong Liu
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 64
Advances and applications of nanoparticles in cancer therapy
Xianzhou Huang, Tao He, Xiuqi Liang, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 28
Enhancing in situ cancer vaccines using delivery technologies
Ningqiang Gong, Mohamad‐Gabriel Alameh, Rakan El‐Mayta, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 8, pp. 607-625
Closed Access | Times Cited: 28
Nanoplatform‐Based In Vivo Gene Delivery Systems for Cancer Therapy
Rui Luo, Hao Le, Qinjie Wu, et al.
Small (2024) Vol. 20, Iss. 30
Closed Access | Times Cited: 17
High‐Z‐Sensitized Radiotherapy Synergizes with the Intervention of the Pentose Phosphate Pathway for In Situ Tumor Vaccination
Yuxiang Wang, Jing Chen, R. Duan, et al.
Advanced Materials (2022) Vol. 34, Iss. 13
Closed Access | Times Cited: 64
Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity
Zhangchi Dongye, Jian Li, Yuzhang Wu
British Journal of Cancer (2022) Vol. 127, Iss. 9, pp. 1584-1594
Open Access | Times Cited: 63
Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant
Jingjing Wei, Di Wu, Songsong Zhao, et al.
Advanced Science (2022) Vol. 9, Iss. 13
Open Access | Times Cited: 58
In vivo fate and intracellular trafficking of vaccine delivery systems
Jaiwoo Lee, Dongyoon Kim, Junho Byun, et al.
Advanced Drug Delivery Reviews (2022) Vol. 186, pp. 114325-114325
Open Access | Times Cited: 49
Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems
Wan Su Yun, Soo Hyun Kim, Dong-Kwon Lim, et al.
Nanomaterials (2023) Vol. 13, Iss. 15, pp. 2225-2225
Open Access | Times Cited: 29
A Dual‐Targeting Liposome Enhances Triple‐Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation
Kaipei Luo, Lu Yang, Chunmei Yan, et al.
Small (2023) Vol. 19, Iss. 40
Closed Access | Times Cited: 23
Emerging nanoparticle platforms for CpG oligonucleotide delivery
Mingqiang Li, Haochen Yao, Ke Yi, et al.
Biomaterials Science (2024) Vol. 12, Iss. 9, pp. 2203-2228
Closed Access | Times Cited: 14
Nanotechnology strategies to address challenges in topical and cellular delivery of siRNAs in skin disease therapy
Ana Vitória Pupo Silvestrini, Milena Finazzi Morais, Bryan Wender Debiasi, et al.
Advanced Drug Delivery Reviews (2024) Vol. 207, pp. 115198-115198
Closed Access | Times Cited: 13
Liposomal STAT3-Degrading PROTAC Prodrugs Promote Anti-Hepatocellular Carcinoma Immunity via Chemically Reprogramming Cancer Stem Cells
Xuan Wang, Youbo Zhao, Xin Li, et al.
Nano Letters (2024)
Closed Access | Times Cited: 10
Combination of Metal‐Phenolic Network‐Based Immunoactive Nanoparticles and Bipolar Irreversible Electroporation for Effective Cancer Immunotherapy
Jun‐Hyeok Han, Ha Eun Shin, Jiyoung Lee, et al.
Small (2022) Vol. 18, Iss. 25
Closed Access | Times Cited: 37
Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis
Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz‐Muñoz, et al.
Small (2022) Vol. 18, Iss. 11
Open Access | Times Cited: 36
In Situ Vaccination with An Injectable Nucleic Acid Hydrogel for Synergistic Cancer Immunotherapy
Fujun Wang, Miao Xie, Yangyang Huang, et al.
Angewandte Chemie International Edition (2023) Vol. 63, Iss. 4
Closed Access | Times Cited: 18
An Adjuvant Micelle-Based Multifunctional Nanosystem for Tumor Immunotherapy by Remodeling Three Types of Immunosuppressive Cells
Siyu Meng, Huiping Du, Xiang Li, et al.
ACS Nano (2024) Vol. 18, Iss. 4, pp. 3134-3150
Closed Access | Times Cited: 7
Immunotherapeutic hydrogel for co-delivery of STAT3 siRNA liposomes and lidocaine hydrochloride for postoperative comprehensive management of NSCLC in a single application
Xianglei Fu, Yanbin Shi, Zili Gu, et al.
Asian Journal of Pharmaceutical Sciences (2024) Vol. 19, Iss. 3, pp. 100925-100925
Open Access | Times Cited: 6
A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis
Jian Li, Jing Qi, Yishu Tang, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 34
Deep Tumor Penetrating Gold Nano‐Adjuvant for NIR‐II‐Triggered In Situ Tumor Vaccination
Anhong Chen, Lei Wu, Yao Luo, et al.
Small (2022) Vol. 18, Iss. 20
Closed Access | Times Cited: 25
An erythrocyte membrane-camouflaged fluorescent covalent organic framework for starving/nitric oxide/immunotherapy of triple-negative breast cancer
Fang Yuan, Cuiling Zhang, Xianzhu Luo, et al.
Chemical Science (2023) Vol. 14, Iss. 48, pp. 14182-14192
Open Access | Times Cited: 16
Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment
Lingxi Jiang, Qi Yao, Lei Yang, et al.
Asian Journal of Pharmaceutical Sciences (2023) Vol. 18, Iss. 5, pp. 100852-100852
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top